Aerosol therapy in patients with cystic fibrosis

Schweizerische Medizinische Wochenschrift

Volumn 127, Issue 5, 1997, Pages 158-164

  Schoni M H ^a   Nikolaizik, W H ^a  

^a Alpine Children's Hospital Davos   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTITRYPSIN; AMILORIDE; ANTIBIOTIC AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; DEOXYRIBONUCLEASE; GENTAMICIN; TOBRAMYCIN;

AEROSOL; CONFERENCE PAPER; CYSTIC FIBROSIS; DEHYDRATION; GENE THERAPY; HUMAN; INFLAMMATION; INHALATIONAL DRUG ADMINISTRATION; MUCOCILIARY CLEARANCE; PATHOPHYSIOLOGY; PATIENT EDUCATION; PHYSIOTHERAPY; RESPIRATORY TRACT INFECTION;

ADMINISTRATION, TOPICAL; ADRENERGIC BETA-AGONISTS; AEROSOLS; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; BRONCHODILATOR AGENTS; CHILD; CYSTIC FIBROSIS; DEOXYRIBONUCLEASES; GLUCOCORTICOIDS; HUMANS; MUCOCILIARY CLEARANCE; RECOMBINANT PROTEINS; RESPIRATORY THERAPY;

EID: 0031049017     PISSN: 00367672     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (53)

1. Denning GM, Ostedgaard LS, Cheng SH, Smith AE, Welsh MJ: Localization of cystic fibrosis transmembrane conductance regulator in chloride secretory epithelia. J Clin Invest 1992; 89: 339-349.
2. Rich DP, Anderson MP, Gregory RJ, Cheng SH, Paul S: Expression of the cystic fibrosis transmembrane conductance regulator corrects defective chloride channel regulation in cystic fibrosis airway epithelial cells. Nature 1990; 347: 358-363.
3. Welsh MJ, Smith AE: Molecular mechanisms of CFTR chloride channel function in cystic fibrosis. Cell 1993; 73: 1251-1254.
4. Stutts MJ, Fitz JG, Paradiso AM, Boucher RC: Multiple modes of regulation of airway epithelial chloride secretion by extracellular ATP. Am J Physiol (Cell Physiol) 1994; 267: C1442-C1445.
5. Sheppard DN, Rich DP, Ostedgaard LO, Gregory RJ, Smith AE: Mutations in CFTR associated with mild disease from chloride channels with altered pore characteristics. Nature 1993; 362: 160-164.
6. Fitz Simmons SC: The changing epidemiology of cystic fibrosis. J Pediatr 1993; 122: 1-9.
7. Niederman MS: The pathogenesis of airway colonization: lessons learned from the study of bacterial adherence. Eur Respir J 1994; 7: 1737-1740.
8. Tsang KWT, Rutman A, Tanaka E, Lund V, Dewar A et al.: Interaction of Pseudomonas aeruginosa with human respiratory mucosa in vitro. Eur Respir J 1994; 7: 1746-1753.
9. Konstan MW, Hilliard KA, Norvell TM, Berger M: Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation. Am J Respir Crit Care Med 1994; 150: 448-454.
10. Konstan MW, Berger M: Infection and inflammation in the lung in cystic fibrosis. In: Davis PB (ed): Cystic fibrosis. New York: Marcel Dekker, 1993.
11. Birrer P, McElvaney NG, Rüdeberg A, Wirz Sommer C, Liechti-Gallati S et al.: Protease-antiprotease imbalance in the lungs of children with cystic fibrosis. Am J Respir Crit Care Med 1994; 150: 207-213.
12. Suter S, Schaad UB, Tegner H, Ohlsson K, Desgrandchamps D, Waldvogel FA: Levels of free granulocyte elastase in bronchial secretions from patients with cystic fibrosis: effect of antimicrobial treatment against Pseudomonas aeruginosa. J Infect Dis 1986; 153: 902-909.
13. Suter S, Schaad UB, Roux-Lombard P, Girardien E, Grau G, Dayer J-M: Relation between tumor necrosis factor alpha and granulocyte elastase alphal-proteinase inhibitor complexes in the plasma of patients with cystic fibrosis. Am J Respir Crit Care Med 1989; 140: 1640-1644.
14. Suter S, Schaad UB, Roux L, Nydegger UE, Waldvogel FA: Granulocyte neutral proteases and Pseudomonas elastase as possible causes of airway damage in patients with cystic fibrosis. J Infect Dis 1984; 149: 523-531.
15. Inoue H, Massion PP, Ueki IF, Grattan KM, Hara M et al.: Pseudomonas stimulates interleukin-8 mRNA expression selectively in airway epithelium, in gland ducts and in recruited neutrophils. Am J Respir Cell Mol Biol 1994; 11: 651-663.
16. Richman-Eisenstat JBY, Jorens PG, Hebert CA, Ueki I, Nadel JA: Interleukin-8: an important chemoattractant in sputum from patients with chronic inflammatory airway diseases. Am J Physiol 1993; 264: L413-L418.
17. Kahn TK, Wagener JS, Boat T, Marinez JS, Accurso FJ, Riches DWH: Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med 1995; 1075-1082.
18. Power C, O'Connor CM, MacFarlane D, O'Mahoney S, Gaffney K et al.: Neutrophil collagenase in sputum from patients with cystic fibrosis. Am J Respir Crit Care Med 1994; 150: 818-822.
19. Accurso FJ, Khan TZ, Wagener JS, Coperhaven SC, Kirchner KK: Does inflammation precede infection in early airways disease? Pediat Pulmonol 1995 (Suppl. 12): 71-72.
20. PB Davis: Evolution of therapy for cystic fibrosis. N Engl J Med 1994; 331: 672-673.
21. Konstan MW, Byard PJ, Hoppel CL, Davis PB: Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med 1995; 332: 848-854.
22. Thomas J, Cook DJ, Brooks D: Chest physical therapy management of patients with cystic fibrosis. A meta-analysis. Am J Respir Crit Care Med 1995; 151: 846-850.
23. Schöni MH: Autogenic drainage: a modern approach to physiotherapy in cystic fibrosis. J Roy Soc Med 1989; 82 (Suppl. 16): 32-37.
24. Weber A: Nebulizer delivery of tobramycin to the lower respiratory tract. Pediatr Pulmonol 1994; 17: 331-339.
25. Matthews LE, Doershuk CF: Inhalation therapy and postural drainage for the treatment of cystic fibrosis. Mod Probl Pediat 1967; 10: 279-314.
26. Zach M, Oberwaldner B, Forche G, Polgar G: Bronchodilators increase airway instability in cystic fibrosis. Am J Respir Crit Care Med 1985; 131: 537-543.
27. König P, Gayer D, Barbero GJ, Shaffer J: Short-term and long-term effects of albuterol aerosol therapy in cystic fibrosis: a preliminary report. Pediatr Pulmonol 1995; 20: 205-214.
28. Høiby N: Antibiotic therapy for chronic infection of Pseudomonas in the lung. Ann Rev Med 1993; 44: 1-10.
29. Touw DJ, Brimicombe RW, Hodson ME, Heijerman HGM, Bakker W: Inhalation of antibiotics in cystic fibrosis. Eur Respir J 1995; 8: 1594-1604.
30. Baran D, De Vuyst P, Ooms HA: Concentration of tobramycin given by aerosol in the fluid obtained by bronchoalveolar lavage. Respir Med 1990; 84: 203-204.
31. Ramsey B, Dorkin HL, Eisenberg JD, Gibson RL, Harwood IR, Kravitz RM: Efficacy of aerolized tobramycin in patients with cystic fibrosis. N Engl J Med 1993; 328: 1740-1746.
32. Ashby BL, Stern DH: Aerolized tobramycin in patients with cystic fibrosis. N Engl J Med 1993; 1659-1660.
33. Ramsey BW, Smith AL: Aerolized tobramycin in patients with cystic fibrosis. N Engl J Med 1993; 329: 1660.
34. Hearst JE, Elliot KE: Identifying the killer in cystic fibrosis. Nature Med 1995; 1: 626-627.
35. Whiteford ML, Wilkinson JA, McColl JA, Conlon FM, Michi JR et al.: Outcome of Burkholderia (Pseudomonas) cepacia colonisation in children with cystic fibrosis following a hospital outbreak. Thorax 1995; 50: 1194-1198.
36. Valerius N, Koch C, Høiby N: Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis early treatment. Lancet 1991/II: 725-726.
37. Schaad UB, Wedgwood-Krucko J, Sutter S, Kraemer R: Efficacy of inhaled amikacin as adjunct to intravenous combination therapy (ceftazidime and amikacin) in cystic fibrosis. J Pediatr 187; 111: 599-605.
38. Knowles MR, Church NL, Waltner WE, Yankaskas JR, Gilligan P et al.: A pilot study of aerolized amiloride for the treatment of lung disease in cystic fibrosis. N Engl J Med 1990; 322: 1189-1194.
39. Graham A, Hasani A, Alton EWFW, Martin GP, Marriott C et al.: No added benefit from nebulized amiloride in patients with cystic fibrosis. Eur Respir J 1993; 6: 1243-1248.
40. Middleton PG, Geddes DM, Alton EWFW: Effect of amiloride and saline on nasal mucociliary clearance and potential differences in cystic fibrosis and normal subjects. Thorax 1993; 48: 812-816.
41. Benali R, Pierrot D, Zahm JM, de Bentzmann S, Puchelle E: Effect of extracellular ATP and UTP on fluid transport by human nasal epithelial cells in culture. Am J Respir Cell Mol Biol 1994; 10: 363-368.
42. Knowles MR, Clarke LL, Boucher RC: Activation by extracellular nucleotides of chloride secretion in the airway epithelia of patients with cystic fibrosis. N Engl J Med 1991; 325: 533-538.
43. Shak S, Capon DJ, Hellniss R, Marsters SA, Baker CL: Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum. Proc Natl Acad Sci USA 1990; 87: 188-192.
44. Dasgupta B, Tomkiewicz RP, Boyd WA, Brow NE, King M: Effects of combined treatment with rhDNase and airway oscillation on spinnability of cystic fibrosis sputum in vitro. Pediatr Pulmonol 1995; 20: 78-82.
45. Range SP, Knox AJ: rhDNase in cystic fibrosis, editorial. Thorax 1995; 50: 321-322.
46. Fuchs HJ, Borowitz DS, Christiansen DH, Morris EM, Nash ML et al.: Effect of aerolized recombinant human DNase on exacerbation of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N Engl J Med 1194; 331: 637-642.
47. Stossel TP, Allen PG, Janmey PA, Käs J, Sheils CA: Actin, DNA, mucolysis of CF sputum in vitro. Pediatr Pulmonol 1994 (Suppl. 10): 102.
48. Shah PL, Scott SF, Fuchs HJ, Geddes DM, Hodson ME: Medium term treatment of stable stage cystic fibrosis with recombinant human DNase I. Thorax 1995; 50: 333-338.
49. Eigen H, Rosenstein BJ, FitzSimmons S, Schidlow DV, and the Cystic Fibrosis Foundation Prednisone Trial Group: A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. J Pediatr 1995; 126: 515-523.
50. Auerbach HS, Williams M, Kirkpatrick JA, Colten HR: Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis. Lancet 1981/II: 686-688.
51. Nikolaizik WH, Schöni MH: Pilot study to assess the effect of inhaled corticosteroids on lung function in patients with cystic fibrosis. J Pediatr 1996; 128: 271-274.
52. Korst RJ, McElvaney NG, Chu C-S, Rosenfeld MA, Mastrangeli A et al.: Gene therapy for respiratory manifestations of cystic fibrosis. Am J Respir Crit Care Med 1995; 151: S75-S87.
53. Knowles MR, Hohneker KW, Zhou Z, Olsen JC, Noah TL et al.: A controlled study of adenoviral-vector-mediated gene transfer in the nasal epithelium of patients with cystic fibrosis. N Engl J Med 1995; 333: 823-831.